Key facts
- SetPoint Medical’s last known valuation is $480.0M (Oct 2025).
- It has raised $580.5M across 7 recorded rounds; the latest was Later Stage VC (Series D) ($115.5M) in Oct 2025.
- Notable investors include Viking Global Investors, New Enterprise Associates, Norwest, Catalio Capital Management, Flare Capital Partners — 29 tracked in total.
- SetPoint Medical has filed 10 Form Ds with the SEC since 2011, most recently Apr 2025 ($115.0M sold to 23 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 7 rounds
- ·The complete investor list — 29 names
- ·Watchlist + deal alerts for SetPoint Medical
Funding rounds
7 roundsAbout SetPoint Medical
Developer of an implantable bioelectronic medical device designed to modulate neuroimmune pathways for reducing inflammation and restoring immunologic balance in chronic autoimmune conditions. The company delivers targeted electrical stimulation to the vagus nerve through a small, wireless implant programmed to provide daily therapy automatically with low maintenance, enabling healthcare providers and patients managing autoimmune diseases such as rheumatoid arthritis to access an alternative to traditional drug treatments with potentially reduced risk and treatment burden.
- Industry
- Therapeutic Devices
- Sector
- Healthcare
- HQ
- Valencia, CA, United States
- Founded
- 2007
- Employees
- 90
- Website
- setpointmedical.com/
- Ownership
- Privately Held (backing)
SetPoint Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SetPoint Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SetPoint Medical in its N-PORT filings yet. We sweep new filings monthly.